JNJ in “America Imports the World's Drug Prices”

Fiscal risk and narrowing rate differentials are redirecting capital toward non-dollar assets and punishing currency-sensitive exporters.

A weaker dollar raises the reported value of Johnson & Johnson's substantial pharmaceutical and medical-technology revenue earned outside the United States.

Rising utilization, tougher reimbursement and scrutiny of denials are shifting economics from insurers back to care providers.

Its MedTech portfolio in orthopedics, electrophysiology and surgery is leveraged to increased procedure volumes when patients face fewer approval barriers.

Western drugmakers are licensing clinically validated Chinese molecules rather than relying solely on expensive in-house discovery.

Johnson & Johnson has already converted a China-origin asset into a global blockbuster through its Legend Biotech partnership for Carvykti.